After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

Eli Lilly's gene-silencing drug lepodisiran has ... inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.